Heron Therapeutics (HRTX) Total Liabilities (2010 - 2026)

Heron Therapeutics (HRTX) has reported Total Liabilities for 17 consecutive years, with $245.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Liabilities fell 5.4% year-over-year to $245.4 million; the trailing twelve-month figure through Jun 2026 stood at $245.4 million (down 5.4% YoY), and the FY2025 full-year result was $241.5 million, down 9.47% from the prior year.
• Total Liabilities climbed to $245.4 million in Q2 2026 per HRTX's latest filing, from $237.1 million in the prior quarter.
• Across five years, Total Liabilities topped out at $266.8 million in Q4 2024 and bottomed at $232.3 million in Q1 2023.
• Historically, Total Liabilities has averaged $250.3 million across 5 years, with a median of $250.7 million in 2022.
• The sharpest annual moves came in 2022 and 2026: Total Liabilities jumped 117.74% in 2022, then fell 10.27% in 2026.
• Over 5 years, Total Liabilities stood at $237.4 million in 2022, then gained by 8.05% to $256.5 million in 2023, then gained by 4.02% to $266.8 million in 2024, then dropped by 9.47% to $241.5 million in 2025, then advanced by 1.58% to $245.4 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $245.4 million, $237.1 million, and $241.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.